...Internship Report On “GSK’S Financial Performance Trend Analysis” Azizur Rahman Submitted By:- 08104091 _ _ _ _ _ _ _ _ _ _ _ _ _ 400 BUS – Spring 2012 . Jabir Al Mursalin Submitted To:- MdLecturer of BRAC Business School BRAC University Dept: BBS Date of Submission: 24th May, 2012 Letter of Endorsement The Internship Report entitled GSK’S Financial Performance Trend Analysis has been submitted for partial fulfillment of the requirements for the degree of Bachelor of Business Administration, Major in Marketing & Finance Faculty of BRAC Business School on Spring 2012 by Mr. Md. Jabir Al Mursalin, Id # 08104091. The report has been accepted and may be presented to the Internship Defense Committee for evaluation. (Any opinions, suggestions made in this report are entirely that of the author of the report. The University does not condone nor reject any of these opinions or suggestions). ______________________ “Mr. Md. Jabir Al Mursalin” Lecturer...
Words: 10391 - Pages: 42
...Internship Report On “GSK’S Financial Performance Trend Analysis” Submitted By:- Azizur Rahman 08104091 _____________ BUS – 400 Spring 2012 Submitted To:- Md. Jabir Al Mursalin Lecturer of BRAC Business School BRAC University Date of Submission: 24 May, 2012 Dept: BBS th Letter of Endorsement The Internship Report entitled GSK’S Financial Performance Trend Analysis has been submitted for partial fulfillment of the requirements for the degree of Bachelor of Business Administration, Major in Marketing & Finance Faculty of BRAC Business School on Spring 2012 by Mr. Md. Jabir Al Mursalin, Id # 08104091. The report has been accepted and may be presented to the Internship Defense Committee for evaluation. (Any opinions, suggestions made in this report are entirely that of the author of the report. The University does not condone nor reject any of these opinions or suggestions). ______________________ “Mr. Md. Jabir Al Mursalin” Lecturer Academic Internship Supervisor Transmittal Message May 24, 2012 Mr. Md. Jabir Al Mursalin Lecturer BRAC Business School Subject: Letter of Transmittal Dear Sir, I am taking the opportunity to submit the report on “GSK’S Financial Performance Trend Analysis" as a requirement of my internship at GlaxoSmithKline Bangladesh Ltd. under the BBA Program of BRAC University -Bangladesh I worked as an Intern in the Secretarial & Legal Division at GSK Bangladesh Ltd. for 12 weeks gaining a working knowledge of the various finance...
Words: 10563 - Pages: 43
...Research and Analysis Project for B.sc (Hons) In Applied Accounting Business and Financial Performance Of GlaxoSmithKline Pakistan Ltd (2007- 2009) XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXX Prepared by Faisal Saleem XXXXXXXXXXXXXXXXXXXXXXXXXXXX XXXXXXXXXXXXXXXXXXXXXXXXXXXX Mentoring by Fahim Ahmed This project is prepared in accordance with Oxford Brookes University guidelines. Table of Contents Topic & Company selection------------------------------------------------------------------------------3 About GlaxoSmithKline------------------------------------------------------------------------------------4 Overview of the Pharmaceutical Industry-------------------------------------------------------------5 Research Aims and Objectives--------------------------------------------------------------------------7 Information Gathering--------------------------------------------------------------------------------------8 Techniques used in RAP--------------------------------------------------------------------------------10 Limitations in RAP and Ethical issues----------------------------------------------------------------11 Financial Analysis-----------------------------------------------------------------------------------------12 Revenue trend Analysis----------------------------------------------------------------------------------12 Profitability and...
Words: 12319 - Pages: 50
...EVOLUTION OF PHARAMA INDUSTRY Market analysis for pharmaceutical company GlaxoSmithKline GlaxoSmithKline is a UK based pharmaceutical, biological and healthcare company. It is the world’s second largest pharmaceutical company. Glaxo Wellcome, which is formed from the merger of Glaxo Laboratories and Burroughs Wellcome & Company, together with the SmithKline Beecham and they have form the GlaxoSmithKline. In the year 2000, GlaxoSmithKline have the name and known as GSK. GSK had employs around 110,000 workers in 117 countries, and is including over 40,000 that participate in sales and marketing. There are few global headquarters which is separated in GSK House in Brebtfort, London, United Kingdom and United States. The London and New York stock exchanges have listed the GSK Company in their list. Some well known brands such as Ribena (beverage), Panadol Zantac (anti-ulcer), Zavirax (anti-viral), (pain relief) and Augmentin (antibiotic) which is selling by them. Mission statement: The GlaxoSmithKline (GSK) global quest is to improve the quality of human life by guiding people to do more, to let them feel better, and also live longer. Besides that, the GSK has to undertake the entrepreneurial spirit of enthusiasm. It is inspired by the constant search for the pursuit of innovation. GlaxoSmithKline attention to performance also made their complete realization and each and every citizen, as a global leader in world-class and unparalleled passion for the success of awareness...
Words: 3608 - Pages: 15
...system is implemented in various sectors of an pharmaceutical company ie. “GlaxoSmithKline Bangladesh Limited”. GlaxoSmithKline Bangladesh Limited carries with it an enviable image and reputation for the past 6 decades. A subsidiary of GlaxoSmithKline (GSK) is one of the world’s largest research-based pharmaceutical and healthcare companies GSK Bangladesh, continues to be committed to improving the quality of human life by enabling people to do more, feel better and live longer. The Company’s principle activities include secondary manufacture of pharmaceutical products and marketing of vaccines, pharmaceutical and healthcare products. GlaxoSmithKline Bangladesh Limited implements many control systems to attain their strategic objectives and competitive advantages. Some models that GlaxoSmithKline uses to make their activities and resources effective & efficient, for their employee performance evaluation and to enhance the overall performance of the organization will be discussed in this paper. Management Control Systems 1.1 Introduction: A management control systems (MCS) is a system which gathers and uses information to evaluate the performance of different organizational resources like human, physical, financial and also the organization as a whole considering the organizational strategies. Finally, MCS influences the behavior of organizational resources to implement organizational strategies. In the...
Words: 4708 - Pages: 19
...avoid actions that reduce the ability of the interested parties, including the future generations to meet their needs. In order to elaborate, how a leading global organization takes Sustainable Supply Chain Management as a strategic goal, we have prepared our report on GSK’s Sustainability elements. GSK is one of the world’s leading research-based pharmaceutical and healthcare companies, developing and supplying medicines to a huge global market. The company employs more than 97,000 people in over 100 countries and has an extensive worldwide supply chain. GSK’s mission is to help people do more, feel better, live longer. They do this through investing in R&D, adopting flexible approaches to pricing, promoting open innovation, and strengthening healthcare systems. By growing their business and extending access to their medicines, GSK ensures long term commercial success as well as creating value for its shareholders and delivering economic benefits to the wider society. GSK contributes directly and indirectly to the economic growth in more than 150 countries through tax, charitable support and employment of 101,255 people around the world. This report reflects the actions taken up by GSK for achieving sustainability in their supply chain operations. GSK’S top 10 sustainability successes have also been highlighted in this report as to how they achieved the Carbon Trust Certification, reduced Carbon footprint,...
Words: 4386 - Pages: 18
...promptly institute a strategic response plan and corrective action and, if necessary, to apologise genuinely and without delay. The paper assesses the case against the theoretical basis of each of these principles and comparable cases. A senior executive of the company concerned was interviewed about some management aspects. Findings – Despite early indications of a problem which had potential impact around the world, a major global corporation responded inadequately to a local situation and, as a result, suffered prolonged embarrassment at the hands of two teenagers and unnecessarily severe damage to its brand and international reputation. Originality/value – By in-depth analysis of a recent case, the paper underlines valuable lessons in terms of prompt management intervention, consistent strategy and effective apologia. It also illustrates the danger of poor management of a brand extension and the risk of contagion facing multinational organizations where adverse outcomes in one small regional market can rapidly damage a global reputation....
Words: 2893 - Pages: 12
...Executive Summary * The figures used for the ratio calculations were taken from the companies’ annual reports using the formulas shown in Exhibit 1. A. Global Pharmaceuticals and Medicine Manufacturing Industry (200 words) The global pharmaceutical and medicine manufacturing industry is one of the most profitable industries in the world. Currently, the industry has revenue of approximately $1.1 billion, with a forecast of growing at an annualised rate of 5.7% to $1.4 trillion by 2020. (Exhibit 4) Some of the reasons for this growth are the increasingly elderly population and rising middle class within emerging markets. Since the global population is aging, there has also been demand for products designed for age-related conditions. Lastly, the emergence of new viruses, pandemics and drug-resistant infections has prompted more research and development (R&D) in the industry, increasing the number of products in the pipeline Concentration in this industry is low, as the large pharmaceutical manufacturers only account for 15% of the market share. The most important issue faced by large pharmaceutical companies globally is the expiration of their patents, which results in the production of generic drugs by other manufacturers at lower price. The last 4 years companies have faced a series of simultaneous patent expiries, leading to severe sales losses of up to $250 billion from 2012 until today. Lastly, global trade and regulations have an impact on pricing controls...
Words: 3225 - Pages: 13
...30208 Section D Table of contents Executive Summary 3 Introduction 4 Vision and Mission 4 Management Structure and Nature 5 Human Resource 8 ENTERPRISE IMAGE AND BRAND EQUITY 9 Performance of the Enterprise 9 References 10 Executive Summary This report studies the internal environment of GlaxoSmithKline (GSK). GSK is a pharmaceutical, vaccines, consumer healthcare, and biologics...
Words: 1656 - Pages: 7
...2 FINANCIAL RATIO ANALYSIS: 2 Purposes and considerations of ratio analysis 2 PHARMACEUTICAL INDUSTRY IN PAKISTAN 3 FEROZSONS LABORATORIES LIMITED 4 LIQUIDITY ANALYSIS RATIOS 4 Current Ratio: 4 Quick Ratio 5 Working Capital: 6 Absolute Liquid Ratio: 8 SOLVENCY RATIOS (Capital Structure Analysis Ratios) 9 Debt Ratio 9 Debt to Equity Ratio 9 Interest Coverage Ratio 10 Equity Ratio 12 Assets to Equity Ratios 13 PROFITABILITY ANALYSIS RATIOS: 14 GENERAL PROFITABILITY: 14 Gross profit ratio/ margin: 15 Operating Expense Ratio: 16 Operating Profit Margin: 17 Net Profit Ratio: 18 OVERALL PROFITABILITY: 19 Earnings per Share (EPS): 19 Return on Equity (ROE): 20 Return on Assets (ROA): 21 Return on Capital Employed: 22 ACTIVITY ANALYSIS RATIOS 23 Operating Cycle 27 Assets Turnover Ratio 30 Working Capital Turnover Ratio 31 CAPITAL MARKET ANALYSIS RATIOS 32 Price earnings ratio(PE): 32 Dividend Yield Ratio 34 Market to Book Ratio 35 Dividend Payout Ratio 36 STATIC ANALYSIS: 37 REFERENCES: 44 INTRODUCTION TO THE PROJECT The project covers the trend analysis of Ferozsons, a pharmaceutical company in Pakistan, and the static analysis of the same with its major rival, Glaxo Smith Kline Pakistan Limited FINANCIAL RATIO ANALYSIS: The financial statements are essential but they are only the starting point for successful financial management. Financial Ratio Analysis is applied to Financial Statements to analyze...
Words: 8084 - Pages: 33
...GlaxoSmithKline company profile Francis Weyzig Amsterdam, October 2004 Summary Business description GlaxoSmithKline (GSK) is one of the world’s largest research-based pharmaceutical corporations that discovers, develops, manufactures and markets branded human health products. Headquarters: UK, with additional operational headquarters in the USA Global presence: about 160 countries Primary markets: USA, France, Germany, UK, Italy and Japan Employees: approximately 103,000 GSK key figures for 2003 (in £ million) Sales 21,441 Materials and production costs 4,188 Marketing and administration 7,563 R&D expenditures 2,770 Operating income 6,920 Net profit 4,765 GSK has two main business divisions, pharmaceuticals and consumer healthcare. This profile deals with the pharmaceuticals division, which generates 85% of GSK’s sales. The five largest selling GSK products are Seretide/Advair for asthma and Chronic Obstructive Pulmonary Disease (COPD); Paxil/Seroxat and Wellbutrin, both antidepression drugs; Avandia/Avadamet for type 2 diabetes; and the antibiotic Augmentin. Each of these drugs generated above £800 million of sales in 2003. GSK produces a broad range of products of special importance to developing countries, including: Anti-malaria drugs Zentel (albendazole), for de-worming and the prevention of lymphatic filariasis Pentosam, against leishmaniasis Anti-retrovirals (ARVs) for the treatment of HIV/AIDS Tuberculosis drugs Vaccines for developing countries Corporate...
Words: 18642 - Pages: 75
...discourse and corporate apologia are to recognize the problem early, to promptly institute a strategic response plan and corrective action and, if necessary, to apologise genuinely and without delay. The paper assesses the case against the theoretical basis of each of these principles and comparable cases. A senior executive of the company concerned was interviewed about some management aspects. Findings – Despite early indications of a problem which had potential impact around the world, a major global corporation responded inadequately to a local situation and, as a result, suffered prolonged embarrassment at the hands of two teenagers and unnecessarily severe damage to its brand and international reputation. Originality/value – By in-depth analysis of a recent case, the paper underlines valuable lessons in terms of prompt management intervention, consistent strategy and effective apologia. It also illustrates the danger of poor management of a brand extension and the risk of contagion facing multinational organizations where adverse outcomes in one small regional market can rapidly damage a global reputation. Keywords Brand image, Corporate image,...
Words: 6368 - Pages: 26
...Equity analysis of GlaxoSmithKline Submitted to Prof. Latha Ramesh Submitted By: Yateendra Agarwal Registration No: 1220344 Section: D Batch: 2012-2014 Christ University Institute of Management Kengri Campus Established in the year 1924 in India GlaxoSmithKline Pharmaceuticals Ltd. (GSK Rx India) is one of the oldest pharmaceuticals company and employs over 3500 people. Globally, GSK is a £ 27.4 billion, leading, research-based healthcare and pharmaceutical company. In India, it is one of the market leaders with a turnover of Rs. 2699 crore and a share of 4.2%. The GSK India product portfolio includes prescription medicines and vaccines. Our prescription medicines range across therapeutic areas such as anti-invectives, dermatology, gynaecology, diabetes, oncology, cardiovascular disease and respiratory diseases. The company is the market leader in most of the therapeutic categories in which it operates. GSK also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenza, chickenpox, diphtheria, pertussis, tetanus, rotavirus, cervical cancer, streptococcus pneumonia and others.GSK's best-in-class field force, backed by a nation-wide network of stockists, ensures that the Company's products are readily available across the nation. GSK has two manufacturing units in India, located at Nashik and Thane as well as a clinical development centre in Bangalore. The state of art plant at Nashik makes formulations while bulk...
Words: 3823 - Pages: 16
...Introduction 2 Malted Milk Market 3 Macro & Micro Environment. 3 Acquisition by GSK – 2002 4 Objectives 4 Positioning Strategy – “Viva Power Booster” 5 Product – “Viva Power Booster” 5 Price – 5 Place - 5 Promotions – 5 Post Launch Evaluation. 5 Recommendation and Action Plan for Repositioning 7 Reference 9 MARKETING TURNAROUND REPOSITIONING VIVA POWER BOOSTER – 2006 Introduction Beginning of GlaxoSmithKline (GSK) could be traced back to early 17th century when, in UK a Company manufacturing and marketing pharmaceuticals and health care products were born. Through several mergers and takeovers the company is now a leading international business entity with a major concentration in India. Venturing into malted milk market in India in a big way the company also acquires an energy booster drink marketed by Shaw Wallace & Hedges Company, branded “Viva” in 2002 in Sri Lanka. In its portfolio the product is marketed along with flagship “Horlicks” brand, a malted milk with a strong brand heritage tracing it’s origins to UK. GSK re-launches “Viva” with several marketing objectives in mind soon after the acquisition. Performance reviews conducted periodically and adverse findings such as stagnant malted milk market size and company’s own share compels GSK to carry out a situational marketing audit involving a strengths, weaknesses, opportunities and threats analysis (SWOT) amidst macro environmental factors (PEST) affecting the performance of the product...
Words: 1803 - Pages: 8
...APPENDIX A - PORTERS 5 FORCES Barriers to Entry • Entering of the potential industrialists is easy, if they have the necessary finances, because the cost of obtaining the permit and start operations is very high. However, there is stiff competition among the companies, especially with the pharmaceuticals, which have not only expanded their scope of operations and distribution through mergers and acquisitions, but also have the necessary know how and long experience to combat any new entrant. • The lengthy and cumbersome registration process, spanning up to two years or more, whereby the new companies have to provide the Certificates of Free Sale, (which confirms the approval for the sale of products in US, Europe, Japan etc) ensure the sale of product in the parent company (incase of MNC) and live up to other irrational clauses in the registration form, inhibit the companies from entering. • The pharmaceutical industry is a very capital intensive industry. This requires large amount of investment, and since, we lag behind in the capital industry, and it has to be imported. Thus, limiting new entrants. • With no stress and emphasis on research and development in our country, it is most likely that the new entrants will produce a new form of the generic type, already being produced in abundance. Thus, the absence of any differential advantage over their competitors will further reduce their chances of survival in the industry. • The risk aversive nature of the industrialists...
Words: 6008 - Pages: 25
